Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Infections

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to Infectious Diseases

Ebola

Ebola hemorrhagic fever (EHF; commonly referred to as simply Ebola) is a recently identified, severe, often fatal infectious disease occurring in humans and some primates caused by the Ebola virus.

The Ebola virus was first discovered in 1976, and since its discovery, different strands of Ebola have caused epidemics with 50 to 90 percent mortality in Za?e, Gabon and Uganda.

The Ebola virus

The Ebola virus comes from the Filoviridae family, similar to the Marburg virus. It is named after the Ebola River in Zaire, Africa, near where the first outbreak in 1976 after a significant outbreak in Yambuku, Zaire (now the Democratic Republic of the Congo), and Nzara, in western Sudan. Of 602 identified cases, there were 397 deaths.

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


The two strains identified in 1976 were named Ebola-Zaire (EBO-Z) and Ebola-Sudan (EBO-S). The outbreak in Sudan showed a lower fatality rate?50%?compared to the 90% mortality rate of the Zaire strain. In 1990, a second, similar virus was identified in Reston, Virginia amongst monkeys imported from the Philippines, and was named Ebola-Reston.

Further outbreaks have occurred in Zaire/Congo (1995 and 2003), Gabon (1994, 1995 and 1996), and in Uganda (2000). A new subtype was identified from a single human case in the C?e d'Ivoire (Ivory Coast) in 1994, EBO-CI.

Of around 1500 identified Ebola cases, two-thirds of the patients have died. The animal (or other) reservoir which sustains the virus between outbreaks has not been identified.

Ebola hemorrhagic fever

Among humans, the virus is transmitted by direct contact with infected body fluids such as blood. The cause of the index case is unknown.

The incubation period of Ebola hemorrhagic fever varies from two days to four weeks. Symptoms are variable too, but the onset is usually sudden and characterized by high fever, prostration, myalgia, arthralgia, abdominal pains and headache. These symptoms progress to vomiting, diarrhea, oropharyngeal lesions, conjunctivitis, organ damage (notably the kidney and liver) by co-localized necrosis, proteinuria, and bleeding both internal and external, commonly through the gastrointestinal tract. Death or recovery to convalescence occurs within six to ten days.

Treatment

No specific treatment has been proven effective, and no vaccine currently exists. A vaccine is in the developmental stages. Ebola is known to exist in humans and a few monkey species can be infected. To develop the vaccine, monkeys are used but it can not be tested on humans except in outbreak environments so the vaccine must be tested extensively and meet strict government regulations. Also, in the development of a vaccine, accessibility and cost for people of poor nations and the transportation efficiency of it must be considered.

Prevention

Although there is no specific treatment for patients with Ebola, there have been entire books written about how to prevent it from spreading from the patient to health care workers or other patients. The first step in prevention is to make advanced preparations for Ebola and other viral hemorrhagic fevers (VHFs). Selecting a VHF Coordinator to oversee preparations for VHF activities, such as the following, does this:

Serving as the focal point for information and leadership when a VHF case is suspected.
Informing all health facility staff about VHFs and the risks associated with them.

Organizing training in VHF Isolation Precautions for staff that will work with VHF patients or infectious body fluids.

Making sure that teams are trained to prepare and transport bodies for burial (CDC 115-116).
The next step is maintaining a minimum standard of cleanliness in the hospital. This includes washing hands and sterilizing needles (CDC 9-18). Also, the medical staff must be informed about the different types of VHFs, including Ebola, and their symptoms. Symptoms that are common to many VHFs are severe weakness and fatigue, and a fever for more than 72 hours and less than three weeks. The patient also may have unexplained bleeding from the mucous membranes, skin, eyes, or gastrointestinal tract. The patient may also be going into shock (has a blood pressure of less than 90 mm Hg or a rapid weak pulse). Finally, that patient may have had contact with someone in the last three weeks that had an unexplained illness with fever or bleeding or who died with an unexplained severe illness with a fever (CDC 23).

The next thing to do is isolate the patient from other patients who may get sick and health care workers who are not directly involved with the patient's care. The patient should be given intravenous support, as he or she is probably dehydrated from losing fluids through vomiting and diarrhea. Finally, if the patient expires, the body should be properly disposed of, preferably through cremation, so that the dead body will not spread disease to other people (CDC 26).

previous.gif (72x17 -- 347 bytes) next.gif (72x17 -- 277 bytes)
 

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.